免疫治疗在头颈部鳞癌中的研究进展  

Research progress of immunotherapy in head and neck squamous cell carcinoma

作　　者：杨帆[1] 王晓华[1] 

机构地区：[1]遂宁市中心医院肿瘤科,四川遂宁629000

出　　处：《海南医学》2017年第19期3205-3207,共3页Hainan Medical Journal

摘　　要：头颈部肿瘤最常见的病理类型为鳞状细胞癌,诊断时常处于疾病晚期。依据肿瘤的位置和分期,头颈部鳞癌传统的治疗方法包括手术、放疗和化疗,但晚期头颈部鳞癌预后差,治疗方法有限。在过去几年中,免疫治疗已发展成为一种新的、很有潜力的肿瘤治疗方法。近期临床试验表明,免疫治疗在头颈部鳞癌中显示出令人满意的疗效,且安全性和耐受性良好。本文将免疫治疗在头颈部鳞癌中的抗肿瘤机制、临床研究进展、生物标志物等做一综述。Squamous cell carcinoma is one of the most common pathological type of the head and neck cancers and often presents an advanced-stage. Traditionally, treatment for squamous cell carcinoma of the head and neck （SCCHN） included surgery, radiation and chemotherapy depending on both the site and stage of disease. However, the prognosis of advanced head and neck squamous cell carcinoma is poor and the treatment is limited. Over the past years, immunotherapy has evolved and become a novel promising strategy for cancer therapy. Recent clinical trials have shown that immunotherapy exhibit satisfactory clinical efficacy, safety and tolerability in the treatment of SCCHN. In this pa-per, the anti-tumor mechanism, clinical research progress and biomarkers of immunotherapy in SCCHN were reviewed.

关 键 词：头颈部鳞癌 免疫治疗 免疫检查点抑制剂 程序性死亡蛋白-1 

分 类 号：R730.261[医药卫生—肿瘤]